InflaRx N.V. (IFRX)
NASDAQ: IFRX · Real-Time Price · USD
1.040
-0.050 (-4.59%)
At close: Jan 9, 2026, 4:00 PM EST
1.090
+0.050 (4.81%)
After-hours: Jan 9, 2026, 7:56 PM EST
InflaRx Revenue
InflaRx had revenue of 23.83K EUR in the quarter ending September 30, 2025, a decrease of -80.75%. This brings the company's revenue in the last twelve months to 62.84K, down -62.71% year-over-year. In the year 2024, InflaRx had annual revenue of 165.79K with 162.79% growth.
Revenue (ttm)
62.84K EUR
Revenue Growth
-62.71%
P/S Ratio
955.62
Revenue / Employee
849 EUR
Employees
74
Market Cap
70.46M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 165.79K | 102.70K | 162.79% |
| Dec 31, 2023 | 63.09K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
IFRX News
- 3 days ago - InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation - GlobeNewsWire
- 12 days ago - InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum - GlobeNewsWire
- 4 weeks ago - InflaRx Announces International Nonproprietary Name of “Izicopan” for INF904 - GlobeNewsWire
- 2 months ago - InflaRx N.V. (IFRX) Discusses Topline Phase 2a Data in Chronic Spontaneous Urticaria and Hidradenitis Suppurativa Transcript - Seeking Alpha
- 2 months ago - InflaRx Reports Positive Phase 2a Data for INF904 in Hidradenitis Suppurative (HS) and Chronic Spontaneous Urticaria (CSU) - GlobeNewsWire
- 2 months ago - InflaRx to Announce Topline Data from Phase 2a Clinical Trial of INF904 in Hidradenitis Suppurativa and Chronic Spontaneous Urticaria - GlobeNewsWire
- 2 months ago - InflaRx Announces Participation in the Guggenheim Securities 2nd Annual Healthcare Innovation Conference - GlobeNewsWire
- 4 months ago - InflaRx Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewsWire